Know more

Amnio-Ring™: Dehydrated  Amniotic Membrane for Ocular Surface Healing

The Amnio-Ring™, developed and patented by Akriti Ophthalmic Pvt Ltd, represents a significant advancement in biologic corneal bandage technology. It combines cryopreserved amniotic membrane with a self-retaining ring design, offering a suture-free, in-office solution for complex ocular surface disorders.

🧿 Amnio-Ring™ by Akriti Ophthalmic Pvt Ltd

Patented, Dehydrated Amniotic Membrane with PMMA Ring

• Type: Dehydrated amniotic membrane ring

• Function: Self-retaining biologic bandage that delivers regenerative healing directly to the cornea

• Design: Ring-based format allows easy placement and retention without sutures

🔬 Technology Overview

• Composition: Dehydrated human amniotic membrane loaded onto a precision-engineered PMMA (polymethylmethacrylate) ring

• Design: Self-retaining ring format enables suture-free, in-office application

• Sterilization: Gamma irradiation ensures sterility and safety

• Shelf Life: Up to 5 years under controlled conditions

🌟 Therapeutic Advantages

• Provides a biologic scaffold for epithelial regeneration

• Rich in growth factors and anti-inflammatory cytokines

• Maintains a moist wound environment, reducing scarring and discomfort

• Offers mechanical stability via PMMA ring, ensuring consistent placement and retention

🌟 Therapeutic Pros

• Modulates inflammation: Reduces cytokine activity and immune cell infiltration

• Promotes regeneration: Stimulates epithelial cell proliferation and nerve healing

• Protective scaffold: Shields the cornea from mechanical stress and desiccation

• Anti-scarring: Inhibits fibroblast activation and collagen deposition

• Antimicrobial: Natural defense against bacterial and viral pathogens

📋 Clinical Applications

• Non-healing corneal ulcers

• Neurotrophic keratitis

• Recurrent corneal erosions

• Chemical burns and dry eye syndrome

• Post-operative epithelial defects and socket reconstruction

📈 Outcomes

• Accelerated epithelial healing (often within 3–7 days)

• Reduced pain, photophobia, and inflammation

• Improved corneal clarity and visual acuity

• High patient comfort and compliance

⚙️ Application Protocol

• Inserted in-office under topical anesthesia

• Retained for 3–5 days depending on severity

• Can be combined with topical antibiotics or lubricants

• Follow-up to assess epithelial closure and symptom relief

🏥 Regulatory & Global Reach

• Patented technology under Akriti’s innovation portfolio

• Certified by ISO 13485, WHO-GMP, CDSCO, and 

• Exported to 30+ countries, contributing to care for over 13 million patients